Jessica Nissi Mamallapalli

Dr. Jessica Nissi Mamallapalli

Medicinal Chemistry, University of Florida, Gainesville, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
Siva Rama Raju KanumuriSiva Rama Raju Kanumuri
Siva Rama Raju Kanumuri
JMJessica Nissi Mamallapalli
Jessica Nissi Mamallapalli
RNRobyn Nelson
Robyn Nelson
CMChristopher R. McCurdy
Christopher R. McCurdy
CMCarol A. Mathews
Carol A. Mathews
ASAbhisheak Sharma
Abhisheak Sharma

Verified
Journal Article
Open access
PDF file
BFBreanne Freeman
Breanne Freeman
JMJessica Nissi Mamallapalli
Jessica Nissi Mamallapalli
TBTengfei Bian
Tengfei Bian
KBKayleigh Maria Ballas
Kayleigh Maria Ballas
ALAllison Lynch
Allison Lynch
CXCheng-Guo Xing
Cheng-Guo Xing
Lung cancer is the leading cause of cancer-related deaths due to its high incidence, late diagnosis, and limited success in clinical treatment. Prevention therefore is critical to help improve lung cancer management. Although tobacco control and tobacco cessation are effective strategies for lung cancer prevention, the numbers of current and former smokers in the USA and globally are not expected to decrease significantly in the near future. Chemoprevention and interception are needed to help high-risk individuals reduce their lung cancer risk or delay lung cancer development. This article will review the epidemiological data, pre-clinical animal data, and limited clinical data that support the potential of kava in reducing human lung cancer risk via its holistic polypharmacological effects. To facilitate its future clinical translation, advanced knowledge is needed with respect to its mechanisms of action and the development of mechanism-based non-invasive biomarkers in addition to safety and efficacy in more clinically relevant animal models.

16 September 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JMJessica Nissi Mamallapalli
Jessica Nissi Mamallapalli
AHAllison Henderson
Allison Henderson
EBErin Berthold
Erin Berthold
SYSaunjoo Yoon
Saunjoo Yoon
DRDiane Ray
Diane Ray
Oliver GrundmannOliver Grundmann
Oliver Grundmann

22 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
JKJason Krehl
Jason Krehl
JMJessica Nissi Mamallapalli
Jessica Nissi Mamallapalli
CXCheng-Guo Xing
Cheng-Guo Xing
Oliver GrundmannOliver Grundmann
Oliver Grundmann
Substance use disorders (SUDs) remain a major public health concern and contribute substantially to compromised quality of life, mortality, and healthcare burden. In the United States alone, millions of individuals are affected by alcohol use disorder (AUD), tobacco use disorder (TUD), and opioid use disorder (OUD), with many cases complicated by co-existing anxiety and stress-related disorders. Piper methysticum G. Forst (kava), a traditional South Pacific plant preparation, has gained attention for its anxiolytic, sedative, and sleep-promoting properties. Its pharmacological effects are primarily attributed to a set of lipophilic compounds known as kavalactones, which have been reported to modulate GABAA receptor activity, dopaminergic and adrenergic signaling pathways, monoamine oxidase-B activity, cannabinoid receptor type 1 activity, and voltage-gated ion channels. Peer-reviewed literature was identified through searches of PubMed, NIH resources, and other scientific databases using terms related to kava, kavalactones, addiction, anxiety, stress, insomnia, and SUDs. Both clinical and preclinical studies were reviewed, including investigations of neurotransmitter systems and addiction-related signaling pathways. The current literature suggests that the strongest rationale for kava use exists in AUD, where anxiety and stress are established contributors to relapse. Evidence supporting kava use in TUD and OUD is largely theoretical, while concerns regarding hepatotoxicity, cytochrome P450 interactions, product variability, and additive risk remain important barriers to its clinical application. In summary, current evidence does not support kava as a replacement for established therapies, while its unique pharmacological profile warrants further investigation as a potential adjunctive treatment for withdrawal and relapse in SUDs.